Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic lymphocytic leukemia: A

Neil Dhopeshwarkar1,2, Wei Yang1,2, Sean Hennessy1,2

  • 1Center for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Abstract

No abstract available in PubMed .